公司資料
Eton Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- ETON
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
61.73 USD (+4.88%)
收盤價
最後更新: 2026年8月17日
751M USD
市值
股價為何變動
As of Aug 17, 2026, ETON closed up 4.88% at $61.73. No new same-company headline was identified in the current news window.
公司概覽
Rare Disease Commercialization Company
Eton Pharmaceuticals develops and commercializes treatments for rare diseases. Its portfolio includes ten commercial products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
Expanding Commercial Portfolio
During 2026, Eton received FDA approval for and launched DESMODA, while also acquiring and relaunching HEMANGEOL. The Eton Cares support platform and rare-disease distribution model are intended to improve access and adherence.
Acquisition and Licensing Model
Eton builds its portfolio by acquiring or licensing products that can be commercialized through a focused rare-disease infrastructure. This allows the company to add approved products and late-stage candidates without relying solely on internally discovered assets.
Late-Stage Pipeline
The company has four late-stage candidates: Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector. Additional work includes a KHINDIVI label expansion, extended-release zinc acetate candidate ET-700, and label harmonization for INCRELEX.
Rare Disease Patient Support
Eton Cares provides reimbursement assistance, product access, and adherence support across the portfolio. A shared patient-services infrastructure allows newly acquired products to be integrated into the company’s existing rare-disease commercial organization.
未來催化劑
- Commercial launch of IMPAVIDO in September 2026.
- Submission of an NDA for AMGLIDIA by the end of 2026.
- First-patient dosing in the INCRELEX label-harmonization study by the end of 2026.
- Potential FDA approval of the expanded KHINDIVI indication in the first half of 2027.
- Initiation of a pivotal study of ET-700 in early 2027, subject to supportive pilot results.
- Submission of an NDA for ASN-001 in the second half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。